Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 16.1B | 2.1% |
| Gross Profit | 9.71B | 0.8% |
| Cost of Revenue | 6.41B | 7% |
| Operating expense | 6.32B | 4.2% |
| Net Income | 5.46B | 14.6% |
| EBITDA | 7.33B | 8.7% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 113B | 6.4% |
| Total Liabilities | 69B | 5.4% |
| Total Equity | 43.6B | 8% |
| Shares Outstanding | 2.53B | 0% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 5.64B | 82.4% |
| Cash from investing | -1.07B | 22.3% |
| Cash from financing | 1.22B | 143.2% |
EPS
Financial Highlights for Merck & Company in Q2 '24
Merck & Company reported a revenue of 16.1B, which is a 2.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 9.71B, marking a -0.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 6.41B, a 7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 6.32B, showing a -4.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 5.46B, showing a 14.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 7.33B, showing a 8.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Merck & Company faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
